Fibrates in CVD: a step towards personalised medicine

The Lancet

Volumn 375, Issue 9729, 2010, Pages 1847-1848

  Staels, Bart ^a,b,c  

^a UNIV LILLE   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; TRIACYLGLYCEROL;

ALBUMINURIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DIABETIC RETINOPATHY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HUMAN; META ANALYSIS; MYOPATHY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; SUDDEN DEATH;

EID: 77952709073     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60758-1     Document Type: Note

References (14)

1. Zanchetti A. Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced?. J Hypertens 27 (2009) 1509-1520
2. Barter J.P., Gotto A.M., LaRosa J.C., et al., for the Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 (2007) 1301-1310
3. Miller M., Cannon C.P., Murphy S.A., et al., for the PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 51 (2008) 724-730
4. Lalloyer F., and Staels B. Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol 30 (2010) 894-899
5. Staels B., Maes M., and Zambon A. Fibrates and future PPARα agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 5 (2008) 542-553
6. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237-1245
7. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999) 410-418
8. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
9. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362 (2010) 1563-1574
10. Jun M., Foote C., Lv J., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375 (2010) 1875-1884
11. Scott R., O'Brien R., Fulcher G., et al., on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome. Diabetes Care 32 (2009) 493-498
12. Barter P.J., and Rye K.A. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?. Arterioscler Thromb Vasc Biol 28 (2008) 39-46
13. Taskinen M.R., Sullivan D.R., Ehnholm C., et al., for the FIELD study investigators. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate. Arterioscler Thromb Vasc Biol 29 (2009) 950-955
14. Davidson M.H., Armani A., McKenney J.M., and Jacobson T.A. Safety considerations with fibrate therapy. Am J Cardiol 99 (2007) 3C-18C